FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2743409171> ?p ?o ?g. }

• W2743409171 abstract "The issue of a therapy of children with juvenile idiopathic arthritis (JIA) with intolerance or insufficient effectiveness of methotrexate remains actual. Objective: Our aim was to study the efficacy and safety of tocilizumab in patients with polyarticular JIA. Methods. In a retrospective study, we studied the results of the use of tocilizumab in patients with active polyarticular JIA ( 5 active joints) resistant to prior therapy with methotrexate or a combination of methotrexate with other nonbiologic disease-modifying antiinflammatory drugs. Results. The data of 40 children (83% girls) with the onset median of polyarticular JIA of 4.8 (2.9, 8.1) years and the interval between the disease onset and the initiation of tocilizumab therapy of 5.7 (1.8, 8.5) years was analyzed. Tocilizumab was used as an intravenous infusion of 8 mg/kg (with a weight 30 kg) or 10 mg/kg (with a weight < 30 kg) every 4 weeks. The duration of tocilizumab monotherapy in 5 (13%) children was 1,109 days (452; 1,542). The stages of inactive disease (according to the criteria of C. Wallace, 2004) in 6 months of tocilizumab therapy reached 6 (15%) patients, in 42 months — 32 (80%) patients. In 3 patients, tocilizumab was canceled due to persistent remission. After 6 months of treatment, there was a marked decrease in erythrocyte sedimentation rate, C-reactive protein concentration, number of leukocytes and platelets (in all cases, p < 0.001) to normal values, which persisted throughout the whole period of drug administration. Predictors for achieving inactive disease were the initial (at the onset of tocilizumab therapy) number of peripheral blood leukocytes < 9.0X109/l [relative risk (RR) 1.92; 95% confidence interval (CI) 0.9–4.6)] and the absence of prior biological therapy (RR 1.92, 95% CI 0.9–4.6). The most frequent side effects of tocilizumab therapy were transient hypercholesterolemia (in 13), hypertriglyceridemia (in 4), transient grade II neutropenia (in 1). Conclusion. The long-term efficacy and relative safety of tocilizumab in children with polyarticular JIA have been showed." @default.
• W2743409171 created "2017-08-17" @default.
• W2743409171 creator A5004670377 @default.
• W2743409171 creator A5004741835 @default.
• W2743409171 creator A5006398471 @default.
• W2743409171 creator A5017098777 @default.
• W2743409171 creator A5040222551 @default.
• W2743409171 creator A5044514857 @default.
• W2743409171 creator A5046519075 @default.
• W2743409171 creator A5053918516 @default.
• W2743409171 creator A5054169292 @default.
• W2743409171 creator A5057813686 @default.
• W2743409171 date "2017-01-01" @default.
• W2743409171 modified "2023-09-27" @default.
• W2743409171 title "The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study" @default.
• W2743409171 doi "https://doi.org/10.15690/vsp.v16i2.1716" @default.
• W2743409171 hasPublicationYear "2017" @default.
• W2743409171 type Work @default.
• W2743409171 sameAs 2743409171 @default.
• W2743409171 citedByCount "0" @default.
• W2743409171 crossrefType "journal-article" @default.
• W2743409171 hasAuthorship W2743409171A5004670377 @default.
• W2743409171 hasAuthorship W2743409171A5004741835 @default.
• W2743409171 hasAuthorship W2743409171A5006398471 @default.
• W2743409171 hasAuthorship W2743409171A5017098777 @default.
• W2743409171 hasAuthorship W2743409171A5040222551 @default.
• W2743409171 hasAuthorship W2743409171A5044514857 @default.
• W2743409171 hasAuthorship W2743409171A5046519075 @default.
• W2743409171 hasAuthorship W2743409171A5053918516 @default.
• W2743409171 hasAuthorship W2743409171A5054169292 @default.
• W2743409171 hasAuthorship W2743409171A5057813686 @default.
• W2743409171 hasBestOaLocation W27434091711 @default.
• W2743409171 hasConcept C115961737 @default.
• W2743409171 hasConcept C126322002 @default.
• W2743409171 hasConcept C167135981 @default.
• W2743409171 hasConcept C2777077863 @default.
• W2743409171 hasConcept C2777178219 @default.
• W2743409171 hasConcept C2777575956 @default.
• W2743409171 hasConcept C54355233 @default.
• W2743409171 hasConcept C71924100 @default.
• W2743409171 hasConcept C86803240 @default.
• W2743409171 hasConceptScore W2743409171C115961737 @default.
• W2743409171 hasConceptScore W2743409171C126322002 @default.
• W2743409171 hasConceptScore W2743409171C167135981 @default.
• W2743409171 hasConceptScore W2743409171C2777077863 @default.
• W2743409171 hasConceptScore W2743409171C2777178219 @default.
• W2743409171 hasConceptScore W2743409171C2777575956 @default.
• W2743409171 hasConceptScore W2743409171C54355233 @default.
• W2743409171 hasConceptScore W2743409171C71924100 @default.
• W2743409171 hasConceptScore W2743409171C86803240 @default.
• W2743409171 hasLocation W27434091711 @default.
• W2743409171 hasLocation W27434091712 @default.
• W2743409171 hasOpenAccess W2743409171 @default.
• W2743409171 hasPrimaryLocation W27434091711 @default.
• W2743409171 hasRelatedWork W1852259590 @default.
• W2743409171 hasRelatedWork W203013145 @default.
• W2743409171 hasRelatedWork W2086555889 @default.
• W2743409171 hasRelatedWork W2096905901 @default.
• W2743409171 hasRelatedWork W2239766345 @default.
• W2743409171 hasRelatedWork W2313698566 @default.
• W2743409171 hasRelatedWork W3013145321 @default.
• W2743409171 hasRelatedWork W3114826977 @default.
• W2743409171 hasRelatedWork W3210359220 @default.
• W2743409171 hasRelatedWork W4230713950 @default.
• W2743409171 isParatext "false" @default.
• W2743409171 isRetracted "false" @default.
• W2743409171 magId "2743409171" @default.
• W2743409171 workType "article" @default.